Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

Launched by THIRD AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jan 15, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a type of medication called nucleoside analogues to see how effective and safe they are for treating patients who have the Hepatitis B virus (HBV) but show normal liver enzyme levels. The study is specifically for adults aged 18 to 65 who have been diagnosed with HBV for more than six months and have not received certain treatments in the last six months. Participants must also have normal levels of a liver enzyme called alanine aminotransferase (ALT), which helps indicate liver health.

If you or someone you know is interested in participating, it’s important to understand that certain health conditions may disqualify potential participants, such as other active liver diseases or serious health issues like cancer or severe diabetes. Those who join the trial can expect to receive the nucleoside analogues and will be monitored for their health and the effectiveness of the treatment. This trial could help improve our understanding of how to better manage Hepatitis B in patients with specific health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Positive hepatitis b surface antigen and hepatitis b antibody \> 0.5 year;
• • Age from 18 to 65 years old;
• • Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;
• • Positive Hepatitis b virus(HBV);
• • Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.
• Exclusion Criteria:
• • Other active liver diseases;
• • Hepatocellular carcinoma or other malignancy;
• • Pregnancy or lactation;
• • Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.